Keyphrases
5-year Survival
20%
Advanced Stage
20%
Antitumor Effect
100%
C57BL
20%
Cancer Immunotherapy
20%
CD11c
20%
CD8+ T Cells
40%
Cervical Cancer
20%
Cisplatin
100%
Cisplatin Treatment
40%
Clinical Grade
20%
Clinical Translation
20%
Conventional Treatment
20%
Current Treatment
20%
Dendritic Cells
20%
E7 Antigen
40%
HPV-16/18
20%
HPV16 E7
40%
Implications for Future
20%
Innovative Therapies
20%
Intratumoral Injection
100%
Invasive Cervical Cancer
20%
Radiation Chemotherapy
20%
Radiation Therapy
20%
Recombinant
20%
Route of Administration
20%
Systemic Antitumor Immune Response
20%
TA-HPV
60%
TC-1
20%
TC-1 Tumor
20%
Therapeutic Vaccine
20%
Treatment Strategy
20%
Tumor
20%
Tumor Model
20%
Tumor Size
20%
Vaccinia Virus
20%
Vaccinium
100%
Immunology and Microbiology
C57BL 6 Mouse
33%
Cancer Immunotherapy
33%
CD11c
33%
Cytotoxic T-Cell
66%
Dendritic Cell
33%
Human Papillomavirus Type 16
100%
Immune Response
33%
Immunology
33%
Survival Rate
33%
Tumor Volume
33%
Vaccinia Vaccine
100%
Vaccinia Virus
33%
Wild Type
33%
Pharmacology, Toxicology and Pharmaceutical Science
Antiinfective Agent
14%
C57BL 6 Mouse
14%
CD8 Antigen
28%
Chemotherapy
14%
Cisplatin
100%
Human Papillomavirus Type 16
42%
Immunotherapy
14%
Malignant Neoplasm
14%
Neoplasm
42%
Route of Administration
14%
Survival Rate
14%
Therapeutic Vaccine
14%
Tumor Model
14%
Uterine Cervix Cancer
28%
Vaccinia Vaccine
100%
Vaccinia Virus
14%